Ceptur Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ceptur Therapeutics, Inc. - overview
Established
2008
Location
-, NJ, US
Primary Industry
Biotechnology
About
Based in New Jersey, US, and founded in 2008, Ceptur Therapeutics, Inc. operates as a biotechnology company that develops genetic medicines for patients with unaddressed diseases based on U1 Adaptor technology. In January 2022 the company completed USD 75 million in Series A financing co-led by venBio Partners and Qiming Venture Partners USA. In 2021 the company licensed and expanded the foundational IP portfolio on U1 Adaptor technology and recruited industry leaders in oligonucleotide therapeutics.
New members of Ceptur's Scientific Advisory Board include Dr. Thomas L. Andresen, CEO of T-Cypher Bio, Dr. Steven.
F. Dowdy, professor of Cellular & Molecular Medicine at UCSD, and other doctors. Ceptur develops genetic medicines using its U1 Adaptor technology. The U1 adaptors are used to engage a ribonucleoprotein splicing factor which is used to promote gene silencing.
This therapy can be used to tackle a wide range of diseases in oncology, the central nervous system, nephrology, and immunology. With the Series A funding from January 2022, Ceptur Therapeutics will build out its team and capabilities and advance novel therapeutics for patients with genetic diseases.
Current Investors
Boxer Capital, LifeSci Partners, Affinity Asset Advisors
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Website
www.cepturtx.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.